- Home
- CMPX vs MNPR Comparison
CMPX vs MNPR Comparison
Compare CMPX & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPX
- MNPR
- Stock Information
- Founded
- CMPX 2014
- MNPR 2014
- Country
- CMPX United States
- MNPR United States
- Employees
- CMPX N/A
- MNPR N/A
- Industry
- CMPX Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- CMPX Health Care
- MNPR Health Care
- Exchange
- CMPX Nasdaq
- MNPR Nasdaq
- Market Cap
- CMPX 291.8M
- MNPR 248.8M
- IPO Year
- CMPX N/A
- MNPR 2019
- Fundamental
- Price
- CMPX $2.97
- MNPR $35.71
- Analyst Decision
- CMPX Strong Buy
- MNPR Strong Buy
- Analyst Count
- CMPX 8
- MNPR 7
- Target Price
- CMPX $13.50
- MNPR $62.00
- AVG Volume (30 Days)
- CMPX 1.3M
- MNPR 20.7K
- Earning Date
- CMPX 08-11-2025
- MNPR 08-12-2025
- Dividend Yield
- CMPX N/A
- MNPR N/A
- EPS Growth
- CMPX N/A
- MNPR N/A
- EPS
- CMPX N/A
- MNPR N/A
- Revenue
- CMPX N/A
- MNPR N/A
- Revenue This Year
- CMPX N/A
- MNPR N/A
- Revenue Next Year
- CMPX N/A
- MNPR N/A
- P/E Ratio
- CMPX N/A
- MNPR N/A
- Revenue Growth
- CMPX N/A
- MNPR N/A
- 52 Week Low
- CMPX $1.15
- MNPR $2.15
- 52 Week High
- CMPX $4.08
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- CMPX 50.84
- MNPR 43.81
- Support Level
- CMPX $2.66
- MNPR $30.51
- Resistance Level
- CMPX $3.47
- MNPR $36.51
- Average True Range (ATR)
- CMPX 0.25
- MNPR 3.33
- MACD
- CMPX -0.02
- MNPR -0.95
- Stochastic Oscillator
- CMPX 38.27
- MNPR 37.55
About CMPX Compass Therapeutics Inc.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.